Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology's stock price increased significantly, with a 98.38% increase from January 13, 2025, to January 9, 2026. Key events include Q3 2025 financial results exceeding estimates due to stronger NERLYNX sales, Q2 2025 financial results also topping estimates, addition to the NASDAQ Biotechnology Index, inducement awards granted to new hires, and reports of insider selling.

Puma Biotechnology's products exhibit some demand seasonality, with the first quarter traditionally being the lowest revenue quarter due to inventory drawdowns after the holiday periods.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to improve cancer care. Their primary product is NERLYNX (neratinib), an oral medication for HER2-overexpressed/amplified breast cancer treatment. The company is also developing alisertib for various cancer indications.

Puma Biotechnology has a global presence, focusing on the United States and international markets. NERLYNX is marketed in the United States, and commercialization rights have been licensed in Europe, Africa, Greater China, Israel, Canada, South East Asia, and Latin America. The company operates subsidiaries in the UK and the Netherlands.

Puma Biotechnology's brand reputation is tied to its financial performance and pipeline developments. MarketBeat indicates a low news sentiment score of 0.21. Analyst sentiment is mixed, with some viewing the company as having weak fundamentals and struggling sales growth, while others see it as undervalued with steady neratinib sales and a promising pipeline. The company's addition to the NASDAQ Biotechnology Index could be seen as a positive.

Puma Biotechnology has a mixed ownership structure, including institutional, retail, and individual investors. Institutional investors hold approximately 32.73% to 45.20% of the stock, insiders hold 16.07%, and public companies and individual investors hold 12.46% to 38.73%. Major institutional owners include Acorn Capital Advisors, Llc, Vanguard Group Inc, and BlackRock, Inc. Alan Auerbach, the company's founder and CEO, owns the most shares individually.